Neomorph, Novo Nordisk enter $1.46bn partnership focused on molecular glue degraders
Neomorph will receive upfront and near-term milestone payments, R&D funding, and milestone payments, totalling $1.46bn from Novo Nordisk,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Feb 24
Neomorph will receive upfront and near-term milestone payments, R&D funding, and milestone payments, totalling $1.46bn from Novo Nordisk,…
23 Feb 24
The collaboration to leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles platform, to develop novel multifunctional biologics in…
13 Sep 23
The exclusive licensing partnership agreement provides Astellas with a total of up to €5.5m, in upfront and milestone…
07 Sep 23
The new research alliance will help advance three programmes over the next three years, of which two programmes…
23 Aug 23
The funding under Project NextGen includes $1bn to BARDA partners for vaccine clinical trials, $326m to Regeneron for…
06 Jul 23
Under the contract, Evotec Biologics will develop drug product prototype(s) from discovery through the execution of Phase 1…
02 Jun 23
The license agreement provides Bayer with exclusive rights to develop and commercialise Cedilla’s CyclinE1/CDK2 inhibitors that are currently…
01 Jun 23
Cobitolimod, a TLR9 agonist, is currently undergoing evaluation in the global phase III programme, known as CONCLUDE, as…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
17 May 23
Astellas and Sony will jointly develop and optimise a new ADC platform using KIRAVIA Backbone as a linker,…
16 May 23
Arcus will receive an upfront payment of $35m and will commence research programs against up to four targets,…